Zepbound

Latest news and articles about Zepbound from NEX English

New Study Shows High-Dose Wegovy Injections Achieve 28% Weight Loss

Novo Nordisk has announced new study results confirming that high-dose Wegovy injections help patients lose nearly 28% of their weight over 72 weeks. This announcement follows the launch of the new dosage in the United States just a month ago.

Launch High-Dose Wegovy at Competitive Prices in Obesity Drug Market

Novo Nordisk has announced the launch of a new high-dose GLP-1 injection for obesity treatment, priced $50 lower than its competitor Zepbound. This release comes amid increasing competition in the obesity medication market.